Whole Genome Sequencing for Preventive Health Decisions

Whole genome sequencing is now accessible enough to enter preventive health decisions, but access alone does not make it useful. Its strongest returns are specific inherited risks and drug-response findings. The value comes from knowing which results can guide care, which need caution, and why genomic information complements ongoing blood testing.

Why WGS is arriving as a preventive health tool right now

Sequencing costs have fallen sharply over the past decade, so whole genome sequencing, or WGS, is now sold to consumers as well as used in research. The breadth is what makes the shift significant. WGS reads nearly all of a person’s DNA base pairs, while a typical consumer genotyping array checks only several hundred thousand pre-selected positions. But what people get varies, from a 30× genome sent as raw files to a clinical report that costs more and has its interpretation signed by a certified geneticist.

Major institutions are also positioning sequencing as prevention. The March 2026 Illumina–Veritas Genetics consortium aims to find risks earlier and use data to guide prevention, with US health insurance plans and global markets as its targets. The UK NHS announced a plan in July 2025 to offer WGS to every newborn within a decade through its 10-Year Health Plan. Genomics England’s Generation Study showed that WGS could identify rare, treatable conditions in about one in every 200 babies. These initiatives make preventive sequencing a serious clinical prospect, though they do not establish its value for every healthy adult.

What WGS reliably finds: single-gene variants with clear clinical meaning

Now that sequencing is accessible, what does it actually deliver? It is best at finding rare monogenic variants, which are changes in a single gene with clear effects on health. A meaningful minority of healthy adults have actionable variants, most often linked to hereditary cancer, inherited heart disease, or familial hypercholesterolemia. For those people, a finding can change care. Even so, people should expect that the test may identify an important finding in a minority of cases, with no guarantee that it will explain their health.

A UK private general-practice feasibility study published in Nature Scientific Reports in 2025 found actionable variants that led to changes in clinical management, covering cancer, cardiac, lipid, and thromboembolic genes. A 2025 Genetic Medicine Open study modeled a comprehensive cardiovascular disease genome test and found monogenic findings in a meaningful share of people, whatever signs or symptoms they had or tests they had already undergone. These findings establish a concrete use for sequencing. They show that clinically relevant inherited risk can be present before someone knows to look for it.

The American College of Medical Genetics and Genomics maintains a list of secondary findings genes that laboratories should report when a harmful variant is found. Almost all are tied to conditions where early action changes outcomes, including hereditary breast and ovarian cancer syndromes, Lynch syndrome, and familial hypercholesterolemia. Here, WGS has a structural advantage over arrays. An array cannot identify a rare or novel variant at a position it was never designed to check, while sequencing can capture it by reading the sequence. The resulting genome can also be reinterpreted as more is learned, new health issues come up, or family planning raises different questions.

Pharmacogenomics: the most immediately useful output most people overlook

Pharmacogenomics examines variants that affect how a person metabolizes or responds to particular drugs, and these findings affect a larger share of sequenced people than rare disease variants do. The return is less dramatic but often practical. A result can inform prescribing before a medication is taken, rather than becoming relevant only after a problem appears.

The specific genes make that value easier to understand. CYP2C19 affects clopidogrel metabolism in ways that matter directly to the heart, while CYP2D6 plays a part in how people respond to many psychiatric and cardiac drugs. SLCO1B1 is linked to statin myopathy risk. For someone taking or thinking of taking a statin for cardiovascular prevention, that finding bears on a treatment choice they already face, even if the risk lies in the future. It does not turn statins into a category to fear, but provides information that can change prescribing decisions.

A 2026 retrospective study in European Journal of Human Genetics found that almost a third of participants who had a rare variant or copy-number variant in a pharmacogene received a changed phenotype classification and treatment recommendation. WGS nevertheless offers broad pharmacogenomic data in a single test, whereas targeted panels cover only a subset of genes. As costs fall, pre-emptive pharmacogenomic testing is expected to become a routine part of care.

Where polygenic risk scores add value — and where they mislead

Polygenic risk scores, or PRS, answer a different question from single-gene findings. They estimate risk by combining many common variants that each have a small effect, rather than finding one variant with a large effect on health. Large genome-wide association studies underpin this approach, including work on cardiovascular disease. A score compares genetic risk with a reference population, leaving an individual’s future uncertain.

What does a result near the top of the distribution actually mean? A high percentile can sound scary without saying how likely someone is to get the disease. For a rare disease, even a substantial relative increase from a low baseline can leave absolute lifetime risk low. Consumer dashboards typically give the percentile more emphasis than that absolute figure. The distinction is between ranking someone against others and estimating their chance of developing the condition.

The reference population also affects the score’s reliability. Scores built predominantly from European-ancestry studies lose meaningful accuracy in people of African ancestry, so the same kind of output does not offer equally dependable information to everyone. That limits how confidently a result can guide care. For a reader with a high coronary artery disease PRS, the useful response is to prioritize measurable, modifiable biomarkers such as ApoB, CRP, fasting glucose, and HbA1c.

What WGS cannot resolve, and why blood biomarkers remain the first-line preventive signal

No major guideline currently recommends WGS as routine screening for healthy adults. The US Preventive Services Task Force limits genetic recommendations to targeted testing for people with qualifying family histories, personal cancer histories, or high-risk ancestries. The evidence gap concerns whether sequencing everyone produces better health across a population, beyond the detection of actionable variants in some people. That broader question is still being studied.

The word “whole” also deserves a careful reading. Standard 30× short-read WGS does not reliably capture repeat-expansion disorders such as Huntington’s, pseudogene regions, or low-level mosaicism, including early somatic mutations relevant to cancer. Epigenetic changes also fall outside its reliable scope. A broadly read genome is therefore not a complete account of every genetic or biological process relevant to health.

Even a detected variant may not have a clear interpretation. Variants of uncertain significance are not well understood, have limited usefulness for preventive action, and can generate anxiety or unnecessary intervention. Pathogenic findings have a different but related limitation. The likelihood that someone with a variant will develop the associated disease, known as penetrance, may be low or depend on context. A report identifying a harmful variant does not automatically establish that its associated disease will occur.

For common chronic diseases such as cardiovascular disease, type 2 diabetes, and metabolic syndrome, blood biomarkers remain the most actionable first-line preventive signals. ApoB, CRP, fasting glucose, and HbA1c reflect what is happening in the body now, including modifiable drivers of risk. Genomics answers a different kind of question. If someone with a high ApoB result also has a familial hypercholesterolemia variant, the variant adds information about inherited risk, but they still need the blood measurement.

The real risks of consumer WGS: incidental findings, data privacy, and the counselor bottleneck

Receiving more information is not always the same as receiving clarity. WGS regularly returns findings in genes unrelated to the original reason for testing, including information about conditions someone may not have chosen to learn about. Some secondary findings have clear clinical value, as the ACMG list reflects. Others need substantial professional context. The difficulty is not simply whether a finding exists, but whether the person receiving it understands its significance and what, if anything, should follow.

DNA is persistently identifying, cannot be changed, and has implications for biological relatives who never consented to testing. The 2023 23andMe breach compromised UK users’ personal data, illustrating that privacy risks are not hypothetical. Population-scale genomic databases also raise concerns about surveillance, misuse, and improper sharing with insurers, pharmaceutical firms, or law enforcement. Once data has been shared, that decision cannot simply be undone.

GINA protects against genetic discrimination in health insurance and employment, but not in life, disability, or long-term care insurance. That gap is relevant to anyone considering sequencing before applying for coverage. It sits outside the scientific accuracy of the test. A technically sound result can still have implications that the person ordering it did not anticipate.

Genetic counselors are already scarce, and demand is likely to grow as sequencing expands. Uncertain findings, context-dependent penetrance, and unexpected results all create a need for help distinguishing useful action from overreaction. Veritas Genetics includes pre- and post-test counselor sessions and lays out reports for a physician to review, so it does more to meet that need than products that give people raw files or app-based reports without clinical support.

How to decide whether WGS belongs in your preventive health picture

The practical decision begins with the question the test is meant to answer. People with a personal or family history of hereditary cancer, early-onset cardiovascular disease, cardiomyopathy, or familial hypercholesterolemia have a higher prior probability of an actionable monogenic finding than the general population. For someone taking or being considered for statins, clopidogrel, or psychiatric medications, pharmacogenomic information can directly affect prescribing. WGS has its strongest rationale when a result could change an identifiable decision.

For a person considering a purchase, the next step is to distinguish sequencing from interpretation. Reading DNA costs less than it used to, but paying more than the baseline price can cover guarantees of coverage depth, sample handling that is CLIA/CAP-regulated, and interpretation by a person. Those are not interchangeable benefits. Human interpretation is the most important variable in whether a finding becomes actionable.

Sequencing.com offers 30× clinical-grade short-read sequencing in the US, with paid turnaround tiers of Standard at 7–8 weeks, Expedited at 4–6 weeks, and Ultra Rapid at 2–3 weeks. Its marketplace provides breadth through third-party apps, while those apps’ privacy policies vary. The consumer options described here range from that marketplace model to the counselor-supported reporting already discussed, rather than differing only in how quickly files arrive.

Before ordering, someone thinking of buying a test should ask whether the lab has CLIA/CAP certification and whether pre-test counseling covers incidental findings. The report’s scope deserves equal scrutiny, including repeat expansions and whether sequencing is low-pass or 30×. Data policy belongs in the same decision. Does the company allow third-party sharing, and what information might leave its platform? These questions help establish what is being purchased and what responsibilities will remain after delivery.

If WGS is chosen, the lesson is to use a clinician-mediated pathway and pair its findings with ongoing biomarker testing. The genome offers a snapshot of inherited risk that can be reinterpreted over time, while ApoB, CRP, HbA1c, fasting glucose, and hormones are dynamic signals that change with lifestyle, age, and intervention. A clinician or clinical team familiar with both can review them together. Preventive health is an ongoing, measurable practice. Its value lies not in possessing a result, but in using appropriate evidence to guide care as health changes.